Accumulating evidence indicates a pivot role of Akt/mTOR pathway in regulating CD4 + Foxp3+ regulatory T cells in tumor microenvironment [32], [33].Therefore, targeting mTOR by rapamycin may be a promising therapeutic strategy for ASCC. The gene discussed is AKT1; the disease is neoplasm.